Trial reportBMC endocrine disorders2021
Control of Graves' hyperthyroidism with very long-term methimazole treatment: a clinical trial.
Trial report in BMC endocrine disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Causal validation of the relationship between 35 blood and urine biomarkers and hyperthyroidism: a bidirectional Mendelian randomization study and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Predictors of Treatment Outcomes in Pediatric Graves' Disease.Journal of Korean medical science · 2026Article
- Treatment outcomes in patients with relapsed Graves' disease.Archives of endocrinology and metabolism · 2026Article
- Graves' disease: review of disease characteristics, burden, and treatments.Frontiers in endocrinology · 2026Review
- Medical Treatment of Hyperthyroidism; Efficacy and Safety Considerations.Archives of Iranian medicine · 2025Review
- A short review of current knowledge regarding long-term treatment of Graves' disease with antithyroid drugs.Hormones (Athens, Greece) · 2025Review
- Management Aspects of Medical Therapy in Graves Disease.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025Review
- Article
- Sustained Euthyroidism during Thionamide Antithyroid Drug Treatment: Comparison of Short- and Long-term Methimazole Therapy.International journal of endocrinology and metabolism · 2024Article
- Hyperthyroidism: A Review.JAMA · 2023Review
- An Effective Straightforward Protocol for the Treatment of Graves' Hyperthyroidism for Primary Care Providers.Current trends in internal medicine · 2023Article
- Long-term management of Graves disease: a narrative review.Journal of Yeungnam medical science · 2023Article
- Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review.Journal of endocrinological investigation · 2022Article
- Methimazole plus levothyroxine for treating hyperthyroidism in children: a systematic review and meta-analysis.Translational pediatrics · 2022Article
- Benefits of Long-Term Continuation of Low-Dose Methimazole Therapy in the Prevention of Recurrent Hyperthyroidism in Graves' Hyperthyroid Patients: A Randomized Prospective Controlled Study.International journal of endocrinology · 2022Article
- Long-Term Antithyroid Drug Treatment of Graves' Disease in Children and Adolescents: A 20-Year Single-Center Experience.Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-term antithyroid drug therapy has become one of the options for treatment of Graves' hyperthyroidism. The aim of this study was to compare thyroid status in those who discontinued methimazole (MMI) treatment after 12.8 years with those who continued MMI as long as 24 years.
methodsFifty nine patients with Graves' disease on long-term MMI for 14.2 ± 2.9 years were recruited; 32 patients (54%) decided to discontinue MMI and 27 (46%) preferred additional years of MMI treatment. All patients were followed for a mean of 6 additional years.
resultsOf 27 patients who continued MMI up to 24 years, suppressed serum thyrotropin (TSH) was not observed in any patient after the seventh year of treatment. Serum free thyroxine, triiodothyronine, TSH and TSH receptor antibody concentrations remained normal up to the length of the study. Mean daily dose of MMI to maintain TSH in the reference range decreased gradually and reached to 2.8 ± 1.7 mg by 24 years of MMI treatment. No adverse reaction related to MMI occured during additional years of therapy. In 32 patients who discontinued MMI, hyperthyroidism relapsed in 6 patients (19%), one left follow-up and 25 (78%) remained euthyroid during the study.
conclusionsLong-term low dose MMI treatment may be a lifelong effective and safe therapeutic modality in patients with Graves' hyperthyroidism for prevention of relapse, if studies from other centers confirm findings of this research.
trial registrationIRCT201009224794N1, 2010-10-25. Retrospectively registered. https://www.irct.ir/trial/5143 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.